


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): A compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof:



wherein Q represents a cyclic group selected from phenyl, pyridyl, pyrrolyl, thienyl, and furyl; one or two hydrogen atoms on the cyclic group are optionally substituted by a substituent selected from the group consisting of a halogen atom, C<sub>1-4</sub> alkyl, nitro, and amino; and p is 2 or 3.

Claim 2 (Original): The compound according to claim 1, wherein Q represents a cyclic group selected from phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-fluorophenyl, 2,6-difluorophenyl, 2,6-dichlorophenyl, 4-methylphenyl, 4-isopropylphenyl, 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 4-chloro-2-nitrophenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-aminophenyl, 3-aminophenyl, 4-aminophenyl, 2-amino-4-chlorophenyl, 1H-2-pyrrolyl, 1H-3-pyrrolyl, 2-thienyl, 3-thienyl, 2-furyl, and 3-furyl.

Claim 3 (Currently Amended): The compound according to claim 1-~~or~~2, wherein p is 2.

Claim 4 (Currently Amended): The compound according to claim 1 or 2, wherein p is 3.

Claim 5 (Original): The compound according to claim 1, wherein Q represents 3-nitrophenyl or 3-aminophenyl and p is 2.

Claim 6 (Original): The compound according to claim 1, which is selected from the group consisting of:

- (1) N5-[1-(2-chlorobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolylamine;
- (2) N5-[1-(3-chlorobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolylamine;
- (3) N5-[1-(4-chlorobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolylamine;
- (4) N5-[1-(4-fluorobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolylamine;
- (5) N5-[1-(2,6-difluorobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolylamine;
- (6) N5-[1-(2,6-dichlorobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolylamine;
- (7) N-(5-isoquinolyl)-N-[1-(4-methylbenzyl)tetrahydro-1H-3-pyrrolyl]amine;
- (8) N5-[1-(4-isopropylbenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolylamine;
- (9) N-(5-isoquinolyl)-N-[1-(2-nitrobenzyl)tetrahydro-1H-3-pyrrolyl]amine;
- (10) N-(5-isoquinolyl)-N-[1-(3-nitrobenzyl)tetrahydro-1H-3-pyrrolyl]amine;
- (11) N-(5-isoquinolyl)-N-[1-(4-nitrobenzyl)tetrahydro-1H-3-pyrrolyl]amine;
- (12) N5-[1-(4-chloro-2-nitrobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolylamine;
- (13) N-(5-isoquinolyl)-N-[1-(2-pyridylmethyl)tetrahydro-1H-3-pyrrolyl]amine;
- (14) N-(5-isoquinolyl)-N-[1-(3-pyridylmethyl)tetrahydro-1H-3-pyrrolyl]amine;
- (15) N-(5-isoquinolyl)-N-[1-(4-pyridylmethyl)tetrahydro-1H-3-pyrrolyl]amine;
- (16) N5-[1-(2-aminobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolylamine;
- (17) N5-[1-(3-aminobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolylamine;

- (18) N5-[1-(4-aminobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolylamine;
- (19) N5-[1-(2-amino-4-chlorobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolylamine;
- (20) N5-[1-(2-chlorobenzyl)-3-piperidyl]-5-isoquinolylamine;
- (21) N5-[1-(3-chlorobenzyl)-3-piperidyl]-5-isoquinolylamine;
- (22) N5-[1-(4-chlorobenzyl)-3-piperidyl]-5-isoquinolylamine;
- (23) N-(1-benzyl-3-piperidyl)-5-isoquinolylamine;
- (24) N5-[1-(2,6-difluorobenzyl)-3-piperidyl]-5-isoquinolylamine;
- (25) N5-[1-(2,6-dichlorobenzyl)-3-piperidyl]-5-isoquinolylamine;
- (26) N-(5-isoquinoliny)-N-[1-(4-methylbenzyl)-3-piperidyl]amine;
- (27) N-(5-isoquinoliny)-N-[1-(4-isopropylbenzyl)-3-piperidyl]amine;
- (28) N-(5-isoquinoliny)-N-[1-(2-nitrobenzyl)-3-piperidyl]amine;
- (29) N-(5-isoquinoliny)-N-[1-(3-nitrobenzyl)-3-piperidyl]amine;
- (30) N-(5-isoquinoliny)-N-[1-(4-nitrobenzyl)-3-piperidyl]amine;
- (31) N5-[1-(4-chloro-2-nitrobenzyl)-3-piperidyl]-5-isoquinolylamine;
- (32) N-(5-isoquinoliny)-N-[1-(2-pyridylmethyl)-3-piperidyl]amine;
- (33) N-(5-isoquinoliny)-N-[1-(3-pyridylmethyl)-3-piperidyl]amine;
- (34) N-(5-isoquinoliny)-N-[1-(4-pyridylmethyl)-3-piperidyl]amine;
- (35) N5-[1-(2-aminobenzyl)-3-piperidyl]-5-isoquinolylamine;
- (36) N5-[1-(3-aminobenzyl)-3-piperidyl]-5-isoquinolylamine;
- (37) N5-[1-(4-aminobenzyl)-3-piperidyl]-5-isoquinolylamine;
- (38) N5-[1-(2-amino-4-chlorobenzyl)-3-piperidyl]-5-isoquinolylamine;
- (39) N-(5-isoquinoliny)-N-[1-(1H-2-pyrrolylmethyl)-3-piperidyl]amine;
- (40) N-(5-isoquinoliny)-N-[1-(1H-3-pyrrolylmethyl)-3-piperidyl]amine;
- (41) N-(5-isoquinoliny)-N-[1-(2-thienylmethyl)-3-piperidyl]amine;
- (42) N-(5-isoquinoliny)-N-[1-(3-thienylmethyl)-3-piperidyl]amine;

- (43) N-[1-(2-furylmethyl)-3-piperidyl]-N-(5-isoquinolyl)amine;
- (44) N-[1-(3-furylmethyl)-3-piperidyl]-N-(5-isoquinolyl)amine;
- (45)(3S)-N5-[1-(3-aminobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolineamine; and
- (46)(3R)-N5-[1-(3-aminobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolineamine.

Claim 7 (Original): The compound according to claim 1, which is selected from (3S)-N5-[1-(3-aminobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolineamine and (3R)-N5-[1-(3-aminobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolineamine and a mixture thereof.

Claim 8 (Currently Amended): A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 7~~ claim 1 or a pharmaceutically acceptable salt or solvate thereof.

Claim 9 (Original): The pharmaceutical composition according to claim 8, for the treatment of a disease mediated by Rho kinase.

Claim 10 (Original): The pharmaceutical composition according to claim 9, wherein the disease mediated by Rho kinase is selected from the group consisting of hypertension, asthma including bronchial asthma, angina pectoris, cerebrovascular contraction, peripheral circulatory disorder, threatened premature birth, glaucoma, constriction of visual field, pollakiuria, cancer, invasion/metastasis of cancer, arteriosclerosis, retinopathy, immune response, inflammation, autoimmune diseases, cerebral dysfunction, osteoporosis, microbism, chronic renal failure, chronic nephritis, diabetic nephropathy, IgA nephropathia, thrombosis-related diseases, rheumatism, impotence, and fibrosis.

Claim 11 (Currently Amended): Use of A method of producing a medicament, which comprises combining a compound according to any one of claims 1 to 7 claim 1 or a pharmaceutically acceptable salt or solvate thereof with a pharmaceutically acceptable carrier, for the manufacture of a medicament in the treatment of diseases mediated by Rho kinase.

Claim 12 (Currently Amended): The use method according to claim 11, wherein the disease mediated by Rho kinase is selected from the group consisting of hypertension, asthma including bronchial asthma, angina pectoris, cerebrovascular contraction, peripheral circulatory disorder, threatened premature birth, glaucoma, constriction of visual field, pollakiuria, cancer, invasion/metastasis of cancer, arteriosclerosis, retinopathy, immune response, inflammation, autoimmune diseases, cerebral dysfunction, osteoporosis, microbiology, chronic renal failure, chronic nephritis, diabetic nephropathy, IgA nephropathia, thrombosis-related diseases, rheumatism, impotence, and fibrosis.

Claim 13 (Currently Amended): A method for treating a disease mediated by Rho kinase, comprising the step of administering a therapeutically effective amount of a compound according to any one of claims 1 to 7 claim 1 or a pharmaceutically acceptable salt or solvate thereof together with a pharmaceutically acceptable carrier, to a mammal.

Claim 14 (Original): The method according to claim 13, wherein the disease mediated by Rho kinase is selected from the group consisting of hypertension, asthma including bronchial asthma, angina pectoris, cerebrovascular contraction, peripheral circulatory disorder, threatened premature birth, glaucoma, constriction of visual field, pollakiuria, cancer, invasion/metastasis of cancer, arteriosclerosis, retinopathy, immune

267275US0PCT

Preliminary Amendment

response, inflammation, autoimmune diseases, cerebral dysfunction, osteoporosis, microbism, chronic renal failure, chronic nephritis, diabetic nephropathy, IgA nephropathia, thrombosis-related diseases, rheumatism, impotence, and fibrosis.